Detalhe da pesquisa
1.
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant ß-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Int J Mol Sci
; 24(10)2023 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37240451
2.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
3.
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Blood
; 124(3): 420-5, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916506
4.
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Blood
; 121(18): 3650-7, 2013 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23525797
5.
Sotatercept in patients with osteolytic lesions of multiple myeloma.
Br J Haematol
; 165(6): 814-23, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24650009
6.
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
Trials
; 24(1): 4, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597128
7.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol
; 9(2): e98-e110, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032434